健帆生物股票讨论区

Jafron BiomedicalLtd's ROE and net income growth match industry average, indicating stable performance. Its high ROE contributes to moderate growth over past five years, with dividends paid over six years. Future expectations show a rise in ROE to 24% and a similar payout ratio, suggesting potential growth momentum.